TABLE 3.
Characteristics of patient and healthy donor (HD) cohort used in T‐cell analysis
| RTX‐treated patients | HD | |
|---|---|---|
| Total, n | 29 | 16 |
| Gender, n | ||
| Male | 17 | 6 |
| Female | 12 | 10 |
| Age, years, median (range) | 66 (37–89) | 67 (62–74) |
| Diagnosis, n | ||
| DLBCL | 8 | ‐ |
| FL | 10 | ‐ |
| tDLBCL | 0 | ‐ |
| HL | 0 | ‐ |
| MZL | 1 | ‐ |
| MCL | 8 | ‐ |
| CLL/SLL | 0 | ‐ |
| Waldenström | 0 | ‐ |
| Burkitt | 2 | ‐ |
| Treatment regimen, n | ||
| R‐Chemo | 12 | ‐ |
| R‐Ibrutinib | 2 | ‐ |
| R‐Len/Ven | 2 | ‐ |
| R‐Mono | 3 | ‐ |
| R‐maintenance | 10 | ‐ |
| Vaccine manufacturer, n | ||
| BioNTech/Pfizer | 19 | 11 |
| Moderna | 9 | 5 |
| Astra/Zeneca | 1 | 0 |
| Days ‐ second vaccine and T1 sample, median (range) | 28 (19–40) | 30 (20–52) |
| HLA class I, n | ||
| A*01:01 | 9 | 4 |
| A*02:01 | 24 | 9 |
| A*03:01 | 5 | 5 |
Abbreviations: Burkitt, Burkitt lymphoma; CLL, chronic lymphocytic leukaemia; (t)DLBCL, (transformed) diffuse large B‐cell lymphoma; FL, follicular lymphoma; HL, Hodgkin lymphoma; Len, lenalidomide; MCL, mantel cell lymphoma; MZL, marginal zone lymphoma; R, rituximab; SLL, small lymphocytic lymphoma; Ven, venetoclax.